Request Demo

Last update 23 Jan 2025

PEAR1

Last update 23 Jan 2025

Basic Info

Synonyms

FLJ00193, hPEAR1, JEDI

+ [5]

Introduction

When overexpressed, reduces the number of both early and late non-adherent myeloid progenitor cells.

Drugs associated with PEAR1

Recombinant humanized anti-PEAR1 monoclonal antibody(Shanghai Xunyao)

Target

PEAR1

Mechanism

PEAR1 inhibitors

Active Org.

Shanghai Xunyao Biotechnology Co., Ltd.

Originator Org.

Shanghai Xunyao Biotechnology Co., Ltd.

Active Indication

Idiopathic Pulmonary Fibrosis

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with PEAR1

NCT06267183

/ RecruitingEarly Phase 1

A Phase I, Single-center, Randomized, Double-blind, Single-dose, Dose-ascending, Placebo-controlled Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.

The purpose of this study is to evaluate safety, tolerability, PK and immunogenicity of SV001 compare to placebo in Chinese healthy adult volunteers.

Start Date12 Jan 2024

Sponsor / Collaborator

Shanghai Xunyao Biotechnology Co., Ltd.

CTR20234287

/ RecruitingPhase 1

单中心、随机、双盲、单次给药、剂量递增、安慰剂对照设计，评价SV001雾化吸入溶液在中国健康成年受试者中的安全性、耐受性、药代动力学特征和免疫原性的I期临床试验

[Translation] A single-center, randomized, double-blind, single-dose, dose-escalation, placebo-controlled Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of SV001 nebulized inhalation solution in healthy Chinese adult subjects

评估SV001雾化吸入溶液单次给药在中国健康成年受试者中的安全性和耐受性。

[Translation]

To evaluate the safety and tolerability of a single dose of SV001 nebulized inhalation solution in healthy Chinese adult subjects.

Start Date08 Jan 2024

Sponsor / Collaborator

Shanghai Xunyao Biotechnology Co., Ltd.

ChiCTR2300072620

/ RecruitingPhase 3

A randomized, double-blind, placebo-controlled clinical study for 52 weeks to evaluate the effect of recombinant anti human GLP-1 receptor humanized monoclonal antibody injection on blood glucose fluctuation and bone metabolism in patients with type 2 diabetes

Start Date01 Jul 2023

Sponsor / Collaborator

NanJing First Pharmaceutical Co., Ltd.

100 Clinical Results associated with PEAR1

100 Translational Medicine associated with PEAR1

0 Patents (Medical) associated with PEAR1

115

Literatures (Medical) associated with PEAR1

01 Jan 2025·Talanta

Highly specific screening of aspirin resistance-related single-nucleotide polymorphisms using ligase chain reaction strategy

Article

Author: Xia, Wei ; Zhan, Xingtong ; Zhang, Zhuo ; Zhou, Xinchen ; Yang, Shuhui ; Jin, Zhuo ; Li, Ying ; Dong, Shuhan ; Liu, Limei ; Wang, Helin ; Wang, Xiangjun ; Jiang, Yan

Aspirin (ASP) is currently the drug of choice for antiplatelet therapy. However, approximately 5%-45 % of patients are resistant to ASP and do not achieve the expected result. At present, a few studies have investigated the correlation between ASP resistance (AR) and single-nucleotide polymorphism (SNP). Traditional detection methods are time-consuming and laborious, affecting the accuracy of personalized medicine. This study aimed to establish a new assay to identify four SNPs associated with AR. A large amount of double-stranded DNA was formed after multiple cycles of specific exponential amplification by ligase chain reaction, the specific melting peak of which was visible in the detection curve, with a detection limit of 10^-11mol/L. The specificity experiments of different proportions of wild-type and mutant plasmid standards showed that the novel method could detect up to 1 % allele frequency and the specificity was good. Clinical blood samples of 57 patients were tested in this study. The results were consistent with those of sequencing and more accurate and reliable than those of the high-resolution melting method. The technique used in this study was simple, sensitive and specific compared with the traditional method. Statistical analysis revealed that AR was significantly correlated with the rs12041331 site of the PEAR1 gene and the rs1695 site of the GSTP1 gene, providing an important reference value for the study of AR.

15 Aug 2024·Journal of Clinical Investigation

LOXL2-induced PEAR1 Ser891 phosphorylation suppresses CD44 degradation and promotes triple-negative breast cancer metastasis

Article

Author: Li, Guoming ; Sun, Xueqing ; Shen, Yingzhi ; Li, Lin ; Yan, Jie ; Fan, Xuemei ; Liu, Junling ; Wu, Xuefeng ; Sun, Huiyan ; Wang, Xinxia ; Liu, Ruoyan ; Han, Baosan ; Zhang, Lin

CD44 is associated with a high risk of metastasis, recurrence, and drug resistance in various cancers. Here we report that platelet endothelial aggregation receptor 1 (PEAR1) is a CD44 chaperone protein that protected CD44 from endocytosis-mediated degradation and enhances cleavage of the CD44 intracellular domain (CD44-ICD). Furthermore, we found that lysyl oxidase-like protein 2 (LOXL2), an endogenous ligand of PEAR1, bound to the PEAR1-EMI domain and facilitated the interaction between PEAR1 and CD44 by inducing PEAR1 Ser891 phosphorylation in a manner that was independent of its enzyme activity. Levels of PEAR1 protein and PEAR1 phosphorylation at Ser891 were increased in patients with triple-negative breast cancer (TNBC), were positively correlated with expression of LOXL2 and CD44, and were negatively correlated with overall survival. The level of PEAR1 Ser891 phosphorylation was identified as the best independent prognostic factor in TNBC patients. The prognostic efficacy of the combination of PEAR1 phosphorylation at Ser891 and CD44 expression was superior to that of PEAR1 phosphorylation at Ser891 alone. Blocking the interaction between LOXL2 and PEAR1 with monoclonal antibodies significantly inhibited TNBC metastasis, representing a promising therapeutic strategy for TNBC.

12 Aug 2024·Combinatorial Chemistry & High Throughput Screening

Electroacupuncture Ameliorates Knee Osteoarthritis By Rebalancing T Cell Homeostasis as Revealed By Immune Repertoire (IR) Sequencing

Article

Author: Zhang, Yunan ; Shi, Guangxia ; Jia, Wenrui ; Huang, Guangrui ; Liu, Cunzhi ; Tu, Jianfeng ; Wang, Tianqi ; Cai, LingYi ; Yang, Jingwen

Background:In this study, we used immune repertoire (IR) sequencing technology to profile the diversity of peripheral blood T cell receptors and used transcriptomics to profile the gene expression of peripheral blood neutrophil mRNA in patients with mild-moderate knee osteoarthritis (KOA) before and after electroacupuncture (EA) treatment.Methods:An 8-week intervention with EA was performed on 3 subjects with KOA. IR sequencing of complementarity determining region 3 (CDR3) was performed using RNA extracted from peripheral blood T cells of KOA subjects prior to and at the end of the intervention, as well as healthy volunteers (controls) who matched the subjects in sex and age. Neutrophils were extracted from the plasma of healthy individuals, pretreatment patients, and posttreatment patients for further transcriptome sequencing.Results:The D50, diversity index (DI), and Shannon entropy values of circulatory T-cells were significantly lower in pretreatment KOA patients compared to healthy controls. Posttreatment KOA samples displayed significant decreases in serum proinflammatory factors, IL-8 and IL-18 (P < 0.01), as well as a substantial reduction in serum matrix MMP-3 and MMP-13 (P < 0.01, P < 0.05). Transcriptome analysis revealed that the expression of CXCL2, IRF8, and PEAR1 (P < 0.05) was significantly higher in patients before the treatment than in the healthy population and was significantly down-regulated after the treatment. In contrast, the expression of SMPD3 (P < 0.05) showed the opposite trend.Conclusion:EA may alleviate KOA by rebalancing T-cell homeostasis and improving systemic inflammation. At the same time, EA treatment can significantly enhance TCR diversity, reduce levels of proinflammatory factors, and increase levels of anti-inflammatory factors, thereby achieving therapeutic effects.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

PEAR1

Basic Info

Related

Analysis